L18I, a more soluble PROTAC with lenalidomide, was able to induce degradation of BTK with multiple mutations in HeLa cells with an average DC50 value of 30 nM, and inhibited growth of lymphoma cells harboring C481S mutant BTK in vitro and in vivo [65]. This evidence concerns the gene BTK and lymphoma.